Boehringer’s Zongertinib Gets FDA Priority Review For HER2 NSCLC
19 Feb 2025 //
GLOBENEWSWIRE
FDA Grants Review To Boehringer’s Zongertinib For HER2-Mutant NSCLC
19 Feb 2025 //
PR NEWSWIRE
19 Feb 2025 //
GLOBENEWSWIRE
19 Feb 2025 //
PR NEWSWIRE